gallstones and semaglutide Gallstones: Safety Facts Is it safe to take

Have questions about GLP-1 medications and your vein health

Clinical Safety Screens Performed MTC personal AND family history in the comorbidity multi-select MEN-2 personal AND family history separately Substance / opioid screen with three-month opiate window + free-text dose, frequency, dates Suicidality and recent suicide attempt as exclusionary opt-out Active cancer treatment and cancer-free-for-five-years exclusionary End-stage kidney and liver disease opt-out Severe GI screen (gastroparesis, blockage, IBD) Pancreatitis history in the multi-select Self-reported blood pressure range and resting heart rate Past 2-month GLP-1 use (semaglutide / tirzepatide / none) No validated PHQ-2 or PHQ-9 depression instrument suicidality is captured as a binary exclusionary opt-out and severe depression is a checkbox on the comorbidity multi-select, but the validated brief screening scale is not used

For doses up to 30 units, a 0.3 mL barrel provides the greatest dosing precision

Always consult with a qualified healthcare provider before starting any treatment, medication, or procedure

After one month of treatment, patients can add the Precision Peptide Genetic Test to map their individual GLP-1 and GIP receptor sensitivity, FTO obesity risk genes, and melanocortin pathway functionidentifying which weight loss mechanism will work most effectively for their specific genetic profile